- Home
- NAMS vs BEAM Comparison
NAMS vs BEAM Comparison
Compare NAMS & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAMS
- BEAM
- Stock Information
- Founded
- NAMS 2019
- BEAM 2017
- Country
- NAMS Netherlands
- BEAM United States
- Employees
- NAMS N/A
- BEAM N/A
- Industry
- NAMS Biotechnology: Pharmaceutical Preparations
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NAMS Health Care
- BEAM Health Care
- Exchange
- NAMS Nasdaq
- BEAM Nasdaq
- Market Cap
- NAMS 3.1B
- BEAM 2.6B
- IPO Year
- NAMS N/A
- BEAM 2020
- Fundamental
- Price
- NAMS $36.14
- BEAM $25.98
- Analyst Decision
- NAMS Strong Buy
- BEAM Strong Buy
- Analyst Count
- NAMS 10
- BEAM 11
- Target Price
- NAMS $43.70
- BEAM $49.40
- AVG Volume (30 Days)
- NAMS 1.4M
- BEAM 2.6M
- Earning Date
- NAMS 11-06-2025
- BEAM 11-05-2025
- Dividend Yield
- NAMS N/A
- BEAM N/A
- EPS Growth
- NAMS N/A
- BEAM N/A
- EPS
- NAMS N/A
- BEAM N/A
- Revenue
- NAMS $64,006,000.00
- BEAM $60,272,000.00
- Revenue This Year
- NAMS N/A
- BEAM N/A
- Revenue Next Year
- NAMS $1.67
- BEAM $19.01
- P/E Ratio
- NAMS N/A
- BEAM N/A
- Revenue Growth
- NAMS 762.15
- BEAM N/A
- 52 Week Low
- NAMS $14.06
- BEAM $13.53
- 52 Week High
- NAMS $41.47
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- NAMS 60.09
- BEAM 50.74
- Support Level
- NAMS $34.34
- BEAM $26.90
- Resistance Level
- NAMS $37.21
- BEAM $28.71
- Average True Range (ATR)
- NAMS 2.47
- BEAM 2.04
- MACD
- NAMS -0.34
- BEAM -0.29
- Stochastic Oscillator
- NAMS 46.32
- BEAM 30.59
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.